Cure My Disease

Don't miss your cure!

 Log in / Sign up

Tailored chemo dosing shows promise for adult leukemia

NCT ID NCT00136435

Completed Disease control Sponsor: Dana-Farber Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase II study tested a personalized dosing approach for the chemotherapy drug L-asparaginase in 100 adults aged 18-50 with newly diagnosed acute lymphoblastic leukemia (ALL). The goal was to see if adjusting doses based on individual drug levels could help more patients complete all 30 planned doses safely. Participants also received other standard chemotherapy drugs. The study measured how many patients finished the full course of L-asparaginase and tracked disease-free survival over four years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
L-asparaginase
What this could lead to
If successful, this could lead to a safer and more effective way to give L-asparaginase to adults with ALL, potentially improving survival rates.
What could go wrong
This is a phase II trial with only 100 participants, so results may not apply to all patients. The treatment involves multiple chemotherapy drugs with known side effects like infection and organ damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute lymphoblastic leukemia Precursor Cell Lymphoblastic Leukemia-Lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE LYMPHOBLASTIC LEUKEMIA

Contacts and locations

Locations

  • Dana-Farber Cancer Institute

    Boston, Massachusetts, 02115, United States

  • Hospital Maisonneuve-Rosemont

    Montreal, Quebec, Canada

  • London Health Sciences Centre

    London, Ontario, Canada

  • Manitoba Blood & Marrow Transplant Program CancerCare Manitoba

    Winnipeg, Manitoba, Canada

  • Massachusetts General Hospital

    Boston, Massachusetts, 02115, United States

  • McMaster University Medical Center

    Hamilton, Ontario, Canada

  • Queen Elizabeth II

    Halifax, Canada

  • Queen's University

    Kingston, Ontario, Canada

  • Royal Victoria Hospital

    Montreal, Quebec, Canada

  • Saskatoon Cancer Centre

    Saskatoon, Saskatchewan, Canada

  • Sunnybrook Health Sciences Centre

    Toronto, Ontario, Canada

  • University Of Columbia Medical Center

    New York, New York, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.